Targeting SYK Kinase in B-Lineage ALL with CD19-Specific C-61 Nanoparticles

描述（由申请人提供）：我们最近发现了五肽模拟物1,4-双（9-0二氢喹啉基）酞嗪/氢奎宁1,4-酞嗪二基二醚（C-61），作为酪氨酸激酶抑制剂靶向SYK的底物结合p位点，作为一种新的候选药物治疗b系急性淋巴细胞白血病（ALL），最常见的儿童癌症形式。在拟开展的多学科转化性研究项目中，我们将制备合理设计的C-61纳米颗粒结构，以更有效地将C-61递送至白血病细胞，进一步提高其效力，拓宽其治疗窗口。在整个项目中，生成的C-61纳米颗粒的抗白血病活性将通过体外和体内实验平台进行评估，包括定量体外细胞凋亡实验、免疫功能小鼠的小鼠bcl - 1白血病模型和人类b系ALL的SCID小鼠异种移植模型。在具体目标1中，我们将通过优化大单层脂质体囊泡的内部核心环境和内层来最大化地包裹C-61，从而开发出有效且稳定的第一代C-61纳米粒结构。在特定目标2下，我们将开发有效的第二代C-61脂质体纳米颗粒，通过用聚乙二醇修饰脂质修饰大单层脂质体囊泡的外层，改善其药效学特性。在Specific Aim 3下，我们将开发CD19定向的第三代C-61纳米颗粒，通过将抗CD19 scFv共价附着在第二代纳米颗粒的外层聚乙二醇化磷脂上。在Specific Aim 4下，我们将研究cd19特异性的第三代C-61纳米颗粒与标准化疗药物的抗白血病活性。在Specific Aim 5下，我们将研究标准抗白血病药物对cd19特异性第3代C-61纳米颗粒结构的毒性、药代动力学和疗效的影响。针对CD19-f白血病细胞syk依赖性抗凋亡存活机制的细胞型特异性纳米颗粒的开发将是克服儿童b系ALL化疗耐药的重要一步。该研究项目的成功完成可能为b系ALL（最常见的儿童癌症）的更有效和潜在的范式转变治疗策略提供基础。我们的研究将带来新的纳米技术发现，预计将为NCI癌症纳米技术联盟的使命做出重大贡献。

DESCRIPTION (provided by applicant): We recently discovered the pentapeptide mimic 1,4-Bis (9-0 dihydroquinidinyl) phthalazine / hydroquinidine 1,4-phathalazinediyl diether (C-61) as a tyrosine kinase inhibitor targeting the substrate-binding P-site of SYK as a novel drug candidate against B-lineage acute lymphoblastic leukemia (ALL), the most common form of childhood cancer. In the proposed translational multidisciplinary research project, we will prepare rationally- designed C-61 nanoparticle constructs for more effective delivery of C-61 to leukemia cells in an attempt to further improve its potency and broaden its therapeutic window. Throughout the project, the anti-leukemic activity of the generated C-61 nanoparticles will be evaluated using in vitro and in vivo assay platforms, including quantitative in vitro apoptosis assays, murine BCL-I leukemia model in immunocompetent mice, and SCID mouse xenograft models of human B-lineage ALL. Under Specific Aim 1, we will develop potent and stable liposomal 1st generation nanoparticle constructs of C-61 by optimizing the intemal core environment and inner monolayer of the large unilamellar liposomal vesicles for maximized C-61 entrapment. Under Specific Aim 2, we will develop potent 2nd generation liposomal nanoparticle constructs of C-61 with improved pharmacodynamic features by modifying the outer monolayer of the large unilamellar liposomal vesicles with poly(ethylene glycol)-modified lipids. Under Specific Aim 3, we will develop CD19- directed 3rd generation nanoparticle constructs of C-61 by incorporating anti-CD19 scFv covalently attached to PEGylated phospholipids in the outer layer of the lead 2nd generation nanoparticles. Under Specific Aim 4, we will study the anti-leukemic activity of the lead CD19-specific 3rd generation C-61 nanoparticle constructs in side by side comparison to standard chemotherapy drugs. Under Specific Aim 5, we will study the effects of standard anti-leukemia drugs on toxicity, pharmacokinetics, and efficacy of the lead CD19-specific 3rd generation C-61 nanoparticle constructs. The development of cell-type specific nanoparticles targeting SYK-dependent anti-apoptotic survival mechanism in CD19-f- leukemic cells will be a significant step forward to overcome chemotherapy resistance in childhood B-lineage ALL. The successful completion of this research project may provide the foundation for a more effective and potentially paradigm-shifting treatment strategy for B-lineage ALL, the most common form of childhood cancer. New nanotechnology discoveries that will result from our research are anticipated to significantly contribute to the mission of the NCI Alliance for Nanotechnology in Cancer.